This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/19/2026
Dormegny-Jeanjean et al (2025)2reported cardiovascular outcomes associated with concomitant use of intranasal SPRAVATO and NS-MAOIs in patients with TRD. A total of 193 SPRAVATO treatment sessions conducted in 13 patients were evaluated retrospectively, including 116 sessions involving concomitant NS-MAOI use. Five patients received an
NS-MAOI (4 received tranylcypromine and 1 received phenelzine). Cardiovascular parameters, including systolic blood pressure, diastolic blood pressure, and heart rate, were assessed at baseline and every 30 minutes for 2 hours following SPRAVATO administration.
A Bayesian random model analysis including 12 patients (2 in the SPRAVATO+NS-MAOI group, 7 in the SPRAVATO-alone group, and 3 who received both) was performed to assess and compare changes in cardiovascular outcomes between SPRAVATO groups. Peak increases in cardiovascular parameters from baseline were observed following SPRAVATO administration; however, these changes were mild and not considered clinically significant. Between the SPRAVATO-alone and SPRAVATO+NS-MAOI groups, no significant differences in cardiovascular parameter changes were observed.
An analysis of factors associated with blood pressure elevation using a Bayesian hierarchical model (183 sessions among all 13 patients) demonstrated that concomitant NS-MAOI treatment was not associated with an increased risk of mild blood pressure elevation (odds ratio [OR], 0.66; 95% plausibility interval, 0.04-12.34) or moderate blood pressure elevation (OR, 0.87; 95% plausibility interval, 0.04-17.51). A hypertensive crisis occurred during 1 treatment session in the SPRAVATO-alone group and no cases suggestive of serotonin syndrome were reported. Limitations include the trial design (the retrospective and non-randomized design restricts extrapolation of the results) and a small sample size.
Wallner et al (2023)3 reported 3 cases of concomitant use of SPRAVATO with MAOIs to treat patients with TRD.
Dunner et al (2020)4 reported on a 61-year-old female patient treated with SPRAVATO concomitantly with tranylcypromine 60 mg. Pertinent medical history included persistent chronic major depressive disorder that was refractory to adequate trials of escitalopram, fluoxetine, bupropion, duloxetine, mirtazapine, augmentation with quetiapine, electroconvulsive therapy, and psychotherapy. The patient experienced a partial response to tranylcypromine therapy initiated at age 57 after a depressive episode.
Treatment was initiated with 28 mg SPRAVATO on the first 2 visits, with blood pressure monitoring every 10 minutes during the first visit. Improvement in anxiety and depression were noted on the first visit. At the third visit, the patient experienced nausea, dizziness, and agitation, with a 56 mg dose resulting in a dose reduction of the final 4 doses of the 4-week treatment. At the end of the acute treatment period, ratings on both patient- and clinician-rated depression and anxiety scales improved and were in the normal range.
Baseline blood pressure ranged from 91-108 mmHg systolic and 56-70 mmHg diastolic. At 40 minutes after dosing, her blood pressure ranged from 99-135 mmHg systolic and 60-82 mmHg diastolic. During treatment, there was no evidence of serotonin syndrome. Mild side effects of dissociation and sedation were observed and dissipated during the 2-hour monitoring period after dosing.
A literature search of MEDLINE®
| 1 | Center for Drug Evaluation and Research. Summary Review. 211243 - SPRAVATO (esketamine) - Reference ID: 4398871. 2019-[cited 2024 June 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000SumR.pdf. |
| 2 | |
| 3 | |
| 4 |
Would you like to clear and leave your conversation? Message history will be lost.